Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 14, Number 3—March 2008

Research

Mycobacterium xenopi Clinical Relevance and Determinants, the Netherlands

Jakko van Ingen*†Comments to Author , Martin J. Boeree*, Wiel C.M. de Lange*, Wouter Hoefsloot*, Saar A. Bendien*, Cecile Magis-Escurra*, Richard Dekhuijzen*, and Dick van Soolingen†
Author affiliations: *Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands; †National Institute for Public Health and the Environment, Bilthoven, the Netherlands;

Main Article

Table 2

Baseline in vitro susceptibility of 47 primary isolates from 42 patients with nontuberculous mycobacterial infection, the Netherlands, January 1999 through March 2005

Susceptibility Drug, no. (%), MIC
Isoniazid Rifampin Ethambutol
Susceptible 9 (21), MIC 0.2 mg/L 29 (69), MIC <1mg/L 5 (12), MIC 5 mg/L
Intermediate 32 (76), MIC 0.5–1.0 mg/L 11 (26), MIC 10 mg/L
Resistant 1 (2), MIC >1 mg/L 13 (31), MIC >1 mg/L 26 (62), MIC >10 mg/L

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO